Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
Heudel P, Frenel JS, Dalban C, Bazan F, Joly F, Arnaud A, Abdeddaim C, Chevalier-Place A, Augereau P, Pautier P, Chakiba C, You B, Lancry-Lecomte L, Garin G, Marcel V, Diaz JJ, Treilleux I, Pérol D, Fabbro M, Ray-Coquard I. Heudel P, et al. Among authors: augereau p. JAMA Oncol. 2022 Jul 1;8(7):1001-1009. doi: 10.1001/jamaoncol.2022.1047. JAMA Oncol. 2022. PMID: 35551299 Free PMC article. Clinical Trial.
Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.
Even C, Pautier P, Duvillard P, Floquet A, Kerbrat P, Troalen F, Rey A, Balleyguier C, Tazi Y, Leary A, Augereau P, Morice P, Droz JP, Fizazi K, Lhommé C. Even C, et al. Among authors: augereau p. Eur J Cancer. 2014 Aug;50(12):2082-9. doi: 10.1016/j.ejca.2014.05.002. Epub 2014 Jun 5. Eur J Cancer. 2014. PMID: 24910417
Vinflunine for the treatment of breast cancer.
Gourmelon C, Bourien H, Augereau P, Patsouris A, Frenel JS, Campone M. Gourmelon C, et al. Among authors: augereau p. Expert Opin Pharmacother. 2016 Sep;17(13):1817-23. doi: 10.1080/14656566.2016.1217991. Epub 2016 Aug 10. Expert Opin Pharmacother. 2016. PMID: 27484180 Review.
Olaparib for the treatment of breast cancer.
Robert M, Frenel JS, Gourmelon C, Patsouris A, Augereau P, Campone M. Robert M, et al. Among authors: augereau p. Expert Opin Investig Drugs. 2017 Jun;26(6):751-759. doi: 10.1080/13543784.2017.1318847. Epub 2017 Apr 21. Expert Opin Investig Drugs. 2017. PMID: 28395540 Review.
Efficacy of buparlisib in treating breast cancer.
Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M. Robert M, et al. Among authors: augereau p. Expert Opin Pharmacother. 2017 Dec;18(18):2007-2016. doi: 10.1080/14656566.2017.1410139. Epub 2017 Dec 1. Expert Opin Pharmacother. 2017. PMID: 29169282
An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
Robert M, Frenel JS, Bourbouloux E, Rigaud DB, Patsouris A, Augereau P, Gourmelon C, Campone M. Robert M, et al. Among authors: augereau p. Drugs. 2018 Sep;78(13):1353-1362. doi: 10.1007/s40265-018-0972-9. Drugs. 2018. PMID: 30143968 Review.
Emerging PARP inhibitors for treating breast cancer.
Robert M, Patsouris A, Frenel JS, Gourmelon C, Augereau P, Campone M. Robert M, et al. Among authors: augereau p. Expert Opin Emerg Drugs. 2018 Sep;23(3):211-221. doi: 10.1080/14728214.2018.1527900. Epub 2018 Sep 29. Expert Opin Emerg Drugs. 2018. PMID: 30251552 Review.
Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.
Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M. Robert M, et al. Among authors: augereau p. Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):85-91. doi: 10.1080/17425255.2019.1559816. Epub 2019 Jan 5. Expert Opin Drug Metab Toxicol. 2019. PMID: 30577708 Review.
91 results